Baidu
map

Antimicrob Agents Chemother:基层医疗门诊中不合理抗生素处方率惊人!

2019-01-18 王淳 环球医学

2018年7月,美国学者发表在《Antimicrob Agents Chemother》的一项研究考察了退伍军人事务部医疗系统内的初级医疗门诊中不合理抗生素处方率。

2018年7月,美国学者发表在《Antimicrob Agents Chemother》的一项研究考察了退伍军人事务部医疗系统内的初级医疗门诊中不合理抗生素处方率。

背景和方法:需要门诊的数据来更好地实施抗菌药物管理。本研究中,研究者审核了医疗系统中初级医生(PCP)开出的门诊抗生素处方的随机样本,并将其与共识指南进行了比较。

结果:12个月中,76名初级医生为40734名患者(中位值600名患者,范围33~1547)开出了3880个急性抗生素处方。初级医生每年为每1000名患者开出中位84个抗生素处方。阿奇霉素(25.8%)、阿莫西林-克拉维酸(13.3%)、多西环素(12.4%)、阿莫西林(11%)、氟喹诺酮类药物(11%)和甲氧苄啶-磺胺甲恶唑(10.6%)为最常开出的处方。研究者深度分析了59名初级医生开出的300个处方的用药记录。这些处方的最常见适应症为急性呼吸道感染(28.3%)、尿路感染(23%)、皮肤和软组织感染(15.7%)和慢性阻塞性肺病(COPD)加重(6.3%)。5.7%的病例中,未列出处方的原因。49.7%的病例未依适应症使用抗生素。12.3%的病例中,依适应症使用抗生素,但是处方的药物与指南不一致。另外14%的病例中,指南一致的抗生素的给药时间未按指南推荐的时间。因此,审核处方的76%是不合理的。环丙沙星和阿奇霉素是最可能的不合理处方。34%的处方为非面对面开具。54.5%的门诊就诊中,抗生素处方未列入初级或二级诊断代码。

结论:门诊不合理抗生素处方的干预空间是巨大的。

原始出处:

Shively NR, et al. Prevalence of Inappropriate Antibiotic Prescribing in Primary Care Clinics within a Veterans Affairs Health Care System. Antimicrob Agents Chemother. 2018 Jul 27;62(8). pii: e00337-18. doi: 10.1128/AAC.00337-18.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1949272, encodeId=2d5919492e217, content=<a href='/topic/show?id=9a4f554245d' target=_blank style='color:#2F92EE;'>#抗生素处方#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55424, encryptionId=9a4f554245d, topicName=抗生素处方)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Tue Apr 09 17:05:00 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084475, encodeId=5e5220844e564, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Wed Dec 11 14:05:00 CST 2019, time=2019-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779577, encodeId=bb751e79577aa, content=<a href='/topic/show?id=0473209562' target=_blank style='color:#2F92EE;'>#agents#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2095, encryptionId=0473209562, topicName=agents)], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=1072181, createdName=wjywjy, createdTime=Sun Sep 15 16:05:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857741, encodeId=b62b185e74191, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Wed Jan 01 01:05:00 CST 2020, time=2020-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779516, encodeId=f9281e79516c6, content=<a href='/topic/show?id=481a2094a9' target=_blank style='color:#2F92EE;'>#Agent#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2094, encryptionId=481a2094a9, topicName=Agent)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Thu Dec 05 23:05:00 CST 2019, time=2019-12-05, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1949272, encodeId=2d5919492e217, content=<a href='/topic/show?id=9a4f554245d' target=_blank style='color:#2F92EE;'>#抗生素处方#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55424, encryptionId=9a4f554245d, topicName=抗生素处方)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Tue Apr 09 17:05:00 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084475, encodeId=5e5220844e564, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Wed Dec 11 14:05:00 CST 2019, time=2019-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779577, encodeId=bb751e79577aa, content=<a href='/topic/show?id=0473209562' target=_blank style='color:#2F92EE;'>#agents#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2095, encryptionId=0473209562, topicName=agents)], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=1072181, createdName=wjywjy, createdTime=Sun Sep 15 16:05:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857741, encodeId=b62b185e74191, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Wed Jan 01 01:05:00 CST 2020, time=2020-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779516, encodeId=f9281e79516c6, content=<a href='/topic/show?id=481a2094a9' target=_blank style='color:#2F92EE;'>#Agent#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2094, encryptionId=481a2094a9, topicName=Agent)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Thu Dec 05 23:05:00 CST 2019, time=2019-12-05, status=1, ipAttribution=)]
    2019-12-11 xjy02
  3. [GetPortalCommentsPageByObjectIdResponse(id=1949272, encodeId=2d5919492e217, content=<a href='/topic/show?id=9a4f554245d' target=_blank style='color:#2F92EE;'>#抗生素处方#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55424, encryptionId=9a4f554245d, topicName=抗生素处方)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Tue Apr 09 17:05:00 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084475, encodeId=5e5220844e564, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Wed Dec 11 14:05:00 CST 2019, time=2019-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779577, encodeId=bb751e79577aa, content=<a href='/topic/show?id=0473209562' target=_blank style='color:#2F92EE;'>#agents#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2095, encryptionId=0473209562, topicName=agents)], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=1072181, createdName=wjywjy, createdTime=Sun Sep 15 16:05:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857741, encodeId=b62b185e74191, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Wed Jan 01 01:05:00 CST 2020, time=2020-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779516, encodeId=f9281e79516c6, content=<a href='/topic/show?id=481a2094a9' target=_blank style='color:#2F92EE;'>#Agent#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2094, encryptionId=481a2094a9, topicName=Agent)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Thu Dec 05 23:05:00 CST 2019, time=2019-12-05, status=1, ipAttribution=)]
    2019-09-15 wjywjy
  4. [GetPortalCommentsPageByObjectIdResponse(id=1949272, encodeId=2d5919492e217, content=<a href='/topic/show?id=9a4f554245d' target=_blank style='color:#2F92EE;'>#抗生素处方#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55424, encryptionId=9a4f554245d, topicName=抗生素处方)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Tue Apr 09 17:05:00 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084475, encodeId=5e5220844e564, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Wed Dec 11 14:05:00 CST 2019, time=2019-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779577, encodeId=bb751e79577aa, content=<a href='/topic/show?id=0473209562' target=_blank style='color:#2F92EE;'>#agents#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2095, encryptionId=0473209562, topicName=agents)], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=1072181, createdName=wjywjy, createdTime=Sun Sep 15 16:05:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857741, encodeId=b62b185e74191, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Wed Jan 01 01:05:00 CST 2020, time=2020-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779516, encodeId=f9281e79516c6, content=<a href='/topic/show?id=481a2094a9' target=_blank style='color:#2F92EE;'>#Agent#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2094, encryptionId=481a2094a9, topicName=Agent)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Thu Dec 05 23:05:00 CST 2019, time=2019-12-05, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1949272, encodeId=2d5919492e217, content=<a href='/topic/show?id=9a4f554245d' target=_blank style='color:#2F92EE;'>#抗生素处方#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55424, encryptionId=9a4f554245d, topicName=抗生素处方)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Tue Apr 09 17:05:00 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084475, encodeId=5e5220844e564, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Wed Dec 11 14:05:00 CST 2019, time=2019-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779577, encodeId=bb751e79577aa, content=<a href='/topic/show?id=0473209562' target=_blank style='color:#2F92EE;'>#agents#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2095, encryptionId=0473209562, topicName=agents)], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=1072181, createdName=wjywjy, createdTime=Sun Sep 15 16:05:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857741, encodeId=b62b185e74191, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Wed Jan 01 01:05:00 CST 2020, time=2020-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779516, encodeId=f9281e79516c6, content=<a href='/topic/show?id=481a2094a9' target=_blank style='color:#2F92EE;'>#Agent#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2094, encryptionId=481a2094a9, topicName=Agent)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Thu Dec 05 23:05:00 CST 2019, time=2019-12-05, status=1, ipAttribution=)]
    2019-12-05 grace5700
Baidu
map
Baidu
map
Baidu
map